327: Biotech's next gold rush, GLP-1 shortages, and STAT Summit highlights

The discussion kicks off with the rising interest in CAR-T therapies for autoimmune diseases. The hosts address the ongoing supply issues of Eli Lilly's weight loss drug and the telehealth platforms behind its distribution. They reflect on the highlights from a major summit that gathered key figures in biopharma and healthcare policy, uncovering insightful strategies and future paths for the industry. The conversation also touches on the unique blend of life philosophy and biotech from a dynamic panel discussion, adding depth to the dialogue.